Back
Speaker illustration

Professor Hans-Dirk Duengen

Scirent - Clinical Research and Science, Berlin (Germany)

Member of:

European Society of Cardiology
Heart Failure Association

Dr. Hans-Dirk Düngen is an accomplished physician at Charité University Hospital Berlin and co-founder of SCIRENT, a full-service contract research organization (CRO). As a senior cardiologist at Charité University Hospital Berlin, he specializes in treating patients with heart failure and has collected a wealth of national and international experience in initiating and executing clinical trials. Also, he is the author of numerous scientific publications. He co-founded SCIRENT in 2012 with the vision to help clients develop innovative medical drugs and devices for patients with cardiovascular diseases. As the CEO of this company, he and his dedicated team of experienced clinical and regulatory professionals provide faster and more efficient clinical trial services in Europe and North America.

Presentations

Effects of the chymase inhibitor fulacimstat on adverse cardiac remodelling after acute myocardial infarction - Results of the CHIARA MIA 2 trial

Event: ESC Congress 2019

Topic: Left Ventricular Remodelling

Session: New strategies in acute coronary syndrome management

Access
Like
Thumbnail

Reliability of peripheral arterial tonometry for assessment of endothelial function in patients with heart failure with preserved and reduced ejection fraction, diabetic nephropathy and arterial hyper

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Pathophysiology

Session: Chronic heart failure

Access
Like
Thumbnail

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of 4 Weeks Treatment with Subcutaneous Elamipretide on Left Ventricular Function in Subjects with Stable Heart Failure with Preserved Ejection Fraction: Rationale and d

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Miscellaneous

Session: Clinical Forum - Sat. 29 April 08:30 - Tues. 02 May at 12:30

Access
Like
Thumbnail

Survival in HFpEF vs HFrEF patients after beta-blocker titration: new insights from the CIBIS-ELD trial

Event: ESC Congress 2016

Topic: Pharmacologic therapy

Session: Heart failure / Left ventricular dysfunction

Access
Like
Thumbnail

Survival in HFpEF vs HFrEF patients after beta-blocker titration: New insights from the CIBIS-ELD trial

Event: HEART FAILURE 2016

Topic: Chronic nursing care

Session: Rapid Fire 3 - Chronic heart failure management

Access
Like
Thumbnail

Effects of beta-blocker therapy on hs-CRP levels in elderly patients with ischemic and non-ischemic heart failure: Results from the CIBIS-ELD trail

Event: HEART FAILURE 2016

Topic: Inflammation

Session: Biomarkers

Access
Like
Thumbnail

Test-retest-reliability of measurement of circulating endothelial and endothelial progenitor cells in peripheral blood in patients with heart failure, diabetic nephropathy and arterial hypertension

Event: HEART FAILURE 2016

Topic: Biomarkers, other

Session: Biomarkers

Access
Like
Thumbnail

Survival in HFpEF vs HFrEF patients after beta-blocker titration: New insights from the CIBIS-ELD trial

Event: EuroHeartCare 2016

Topic: Heart failure

Session: Heart failure

Access
Like
Thumbnail

Effects of beta-blocker therapy on hs-CRP levels in elderly patients with ischemic and non-ischemic heart failure: Results from the CIBIS-ELD trail

Event: EuroHeartCare 2016

Topic: Heart failure

Session: Heart failure

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources